Tissue preparations.
The clinical source trail.
Twelve recovered institute reports and a separately indexed Sigumir publication. These are source records, not thirteen independently validated trials.
How to read these reports
The reports below are available through commercial reproductions. Their existence is useful for tracing research, but does not authenticate the original protocol or establish independent peer review. Study dates are distinguished from the dates of later websites and compilations.
Compare treatment groups, baseline differences and co-treatments before interpreting a result. A significant change within one group is not necessarily a significant difference between groups. Small samples and short observation periods leave substantial uncertainty about clinical benefit and safety.
Cerluten ↗
Profile and linked evidence
Sigumir ↗
Profile and linked evidence
Svetinorm ↗
Profile and linked evidence
Ventfort ↗
Profile and linked evidence
Suprefort ↗
Profile and linked evidence
Vladonix ↗
Profile and linked evidence
Endoluten ↗
Profile and linked evidence
Chelohart ↗
Profile and linked evidence
Glandokort ↗
Profile and linked evidence
Gotratix ↗
Profile and linked evidence
Pielotax ↗
Profile and linked evidence
Taxorest ↗
Profile and linked evidence
Recovered records
Cerluten: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.
- Population / setting
- 85 patients: 48 adjunctive Cerluten; 37 conventional-care controls. Mixed neurological diagnoses.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Random allocation and blinding are not documented. EEG assessment selected more severely affected patients; the findings cannot establish stroke recovery or benefit in healthy people.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Sigumir: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement.
- Population / setting
- 64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Svetinorm: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes symptoms and liver laboratory markers. Its significance markers compare results with baseline; ALT also improved with conventional care.
- Population / setting
- 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- A within-group change is not proof of superiority over controls. Mixed diagnoses, co-treatments and incomplete allocation reporting limit interpretation.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Ventfort: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
- Population / setting
- 49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- The table contains inconsistent sex subtotals. Lipid-table significance is relative to baseline; it does not establish fewer cardiovascular events.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Suprefort: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes digestive-enzyme trends and glucose outcomes. The two-hour glucose comparison is marked significant against controls; fasting changes are marked against baseline.
- Population / setting
- 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Vladonix: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes lymphocyte and immunoglobulin measurements after 15–20 days. Table significance is relative to baseline.
- Population / setting
- 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Endoluten: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
The report describes 15–30-day treatment, endocrine and immune markers, and symptoms. Randomization is asserted without its method.
- Population / setting
- 163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Subgroups must not be pooled into one efficacy result. This oral-preparation report cannot inherit long-term Epithalamin mortality findings. The linked page commercially reproduces the report.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Chelohart: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
The report describes 30-day treatment and exercise-test outcomes.
- Population / setting
- 32 angina patients: 22 adjunctive Chelohart; 10 controls.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- A larger numerical improvement is not necessarily a significant between-group difference. Allocation, blinding and complete adverse-event collection need verification from original study documentation.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Glandokort: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Adrenal/stress report with hormone measurements.
- Population / setting
- 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
- What was checked
- English compilation, PDF pages 25 onward; selected report text/tables checked. Russian original not reconciled.
Limitations & review scope
- Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Gotratix: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Grip/jump improved within-group; step/flexibility findings were nonsignificant.
- Population / setting
- Table: 22 treated, 17 controls; reconcile with original enrollment.
- What was checked
- English compilation, PDF pages 29 onward; selected report text/tables checked. Russian original not reconciled.
Limitations & review scope
- Training effects and unclear allocation prevent a causal performance conclusion. Do not substitute within-group significance for a between-group treatment effect.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Pielotax: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Randomization asserted; renal laboratory outcomes reported.
- Population / setting
- Gouty nephropathy: 27 treated, 15 controls.
- What was checked
- English compilation, PDF pages 43 onward; selected report text/tables checked. Russian original not reconciled.
Limitations & review scope
- Sequence generation, concealment and long-term outcomes remain unresolved. Laboratory-marker changes do not establish prevention of kidney failure.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Taxorest: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
Thirty-day adjunctive report with respiratory measurements.
- Population / setting
- 52 smokers with bronchitis: 31 treated, 21 controls.
- What was checked
- English compilation, PDF pages 63 onward; selected report text/tables checked. Russian original not reconciled.
Limitations & review scope
- Allocation and blinding are not established. Within-group improvement cannot establish superiority or protection against smoking-related disease.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age
Named tissue-derived preparation · Journal publication
A. K. Iordanishvili, V. V. Samsonov, L. N. Soldatova, A. A. Polens, G. A. Ryzhak · Adv Gerontol. 2012;25(1):181–186. PMID 22708467
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
- Population / setting
- 62 older patients with temporomandibular joint diseases
- What was checked
- PubMed citation and abstract checked; full paper not reviewed.
Limitations & review scope
- The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired.
- This is a distinct joint-disease report, not replication of every claim in the earlier institute report.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
What is still missing?
Signed Russian originals, complete protocols, allocation procedures, participant flow, prespecified endpoints, adverse-event collection and independent replication remain recovery priorities. Translation and transcription errors require comparison with the original scans.
Visoluten remains an acquisition target: no study-level clinical record has been established for it in this update. Bonothyrk, Stamakort, Chitomur, Testoluten, Zhenoluten, Tireogen and Libidon still require their own report appraisal. Related tissue preparations and synthetic peptides cannot fill those gaps by association.
Peptide evidence map · Bibliography and PDF sources · Citable research library